Europe Cardiac Safety Services Market – Industry Trends and Forecast to 2029

  • Medical Devices
  • Published Report
  • May 2022
  • Europe
  • 350 Pages
  • No of Tables: 113
  • No of Figures: 36

Europe Cardiac Safety Services Market, By Services (ECG/Holter Measurements, Blood Pressure Measurements, In Vitro Cardiac Safety Assessment Services, Cardiovascular Imaging, Real-Time Telemetry Monitoring, Central Over-Read of ECGS, Non-Invasive Cardiac Imaging, Physiologic Stress Testing, Thorough QT Studies, TQT and Exposure Response Modeling, Platelet Aggregation and Other Services), Phase (Phase 1, Phase 2 and Phase 3), Type (Integrated Services and Standalone Services), End User (Pharmaceuticals & Biopharmaceuticals Companies, Contract Research Organizations and Academic and Research Institute) Industry Trends and Forecast to 2029.

Europe Cardiac Safety Services Market

Market Analysis and Insights

Europe cardiac safety services market is driven by the factors such as an increase in the number of clinical trials, a growing number of the major market players and the innovation in technology, which enhance its demand, as well as increasing investment in research and development, leads to the market growth. Currently, various research studies are taking place, which is expected to create a competitive advantage for manufacturers to develop new and innovative cardiac safety services systems, which is expected to provide various other opportunities in the cardiac safety services market. However, the strict government regulations on approval are expected to hamper the growth.

Europe cardiac safety services market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for safe distribution of machine and drugs products are the major drivers that propelled the market's demand in the forecast period.

Europe cardiac safety services market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that Europe cardiac safety services Market will grow at a CAGR of 14.8% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Pricing in USD

Segments Covered

By Services (ECG/Holter Measurements, Blood Pressure Measurements, In Vitro Cardiac Safety Assessment Services, Cardiovascular Imaging, Real-Time Telemetry Monitoring, Central Over-Read of ECGS, Non-Invasive Cardiac Imaging, Physiologic Stress Testing, Thorough QT Studies, TQT and Exposure Response Modeling, Platelet Aggregation and Other Services), Phase (Phase 1, Phase 2 and Phase 3), Type (Integrated Services and Standalone Services), End User (Pharmaceuticals & Biopharmaceuticals Companies, Contract Research Organizations and Academic and Research Institute)

Countries Covered

Germany, France, U.K., Italy, Spain, Turkey, Russia, Netherlands, Switzerland, Belgium and Rest of Europe

Market Players Covered

Koninklijke Philips N.V., Laboratory Corporation of America Holdings, IQVIA, Medpace, Ncardia, Certara, Eurofins Scientific, SGS SA, Banook, and Celerion among others

Market Definition:

Cardiac safety services generally help support and design clinical trials and other research needed to monitor heart safety. The demand for cardiac safety services market has been increased in both developed well as in developing countries and the reason behind this is the increasing number of clinical trials and product launch. The cardiac safety services market is growing due to introduction of innovative products, increasing in technological products and rising disposable income. The market will grow in forecasted period due to exploration of emerging markets, strategic initiatives by market players, increasing healthcare expenditure.

Europe Cardiac Safety Services Market Dynamics

Drivers

  • Increase in the number of clinical trials

A clinical trial is a well-structured system that is way back hundreds of years and is still the backbone of the regulatory requirements required for a drug to be approved. Recently there has been much advancement in the clinical trial field, which has increased the number of clinical trials and is expected to propel the market growth.

There have been various changes in the regulatory of the clinical trials, which has increased the number of clinical trials and their positive results-

For instance,

  • According to the article by Medical News, there has been a significant increase in the number of trials due to the rise in the quality of clinical trials, such as mandatory training of all staff. Also, in 2017, NIH stated that all investigators and staff should be trained on good clinical practice (GCP) in trials that NIH funds

Increase in healthcare expenditure and funding

The expanse of money used by a country on its healthcare and its growth rate over time is inclined by a wide variety of economic and social factors, including the financing arrangements and structure of the organization of the health system.

Healthcare expenditure has increased across developed countries and emerging economies as the disposable income of people are growing. The more money is spent on healthcare; the healthier a country's population is.

Opportunity

  •  Increase in new drug development

The clinical trials are vital for discovering and developing new drugs for disease treatment. It is the best way researchers can find out what treatments work or don't work on humans. The drug development is characterized as forming new treatment as medicines or devices for curing various diseases such as cancer, endocrine, metabolic, and others.

  • Thus, clinical trials are the most effective way to ensure the safety and efficacy of the therapeutic drug before launching in the market and human consumption that includes cardiac safety evaluation which is an essential part before any medical product goes into the market

Restraint/Challenge

The proper assessment and reporting of clinical cardiac safety data is essential. Approval and product recall for any medical products depend on cardiac safety evaluation. So it is necessary to provide and conduct cardiac safety evaluation according to the legal procedure, otherwise it leads to late approval of the product which is expected to restrain the market growth.

For instance,

  • According to the article by IQVIA, there were 47 instances of post-marketing withdrawal of drugs between 1957 and 2007, in which 45% of these were due to concerns regarding cardiovascular toxicity. Similarly, 27% of the potential new drug molecules that failed in the preclinical phase in the last two decades did so because of cardiovascular toxicity as they did not meet the required regulatory

Europe Cardiac Safety Services Market Segmentation

Europe cardiac safety services market is categorized into type, services, phase and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Services

  • ECG/holter measurements
  • Blood pressure measurements
  • In vitro cardiac safety assessment services
  • Cardiovascular imaging
  • Real-time telemetry monitoring
  • Central over-read of ECGS
  • Non-invasive cardiac imaging
  • Physiologic stress testing
  • Thorough QT studies
  • TQT and exposure response modeling
  • Platelet aggregation
  • Other services

On the basis of services, the cardiac safety services market is segmented into ECG/Holter measurements, blood pressure measurements, in vitro cardiac safety assessment services, cardiovascular imaging, real-time telemetry monitoring, central over-read of ECGS, non-invasive cardiac imaging, physiologic stress testing, thorough QT studies, TQT and exposure response modeling, platelet aggregation and other services

Phase

  • Phase 1
  • Phase 2
  • Phase 3

On the basis of phases, the cardiac safety services market is segmented into phase 1, phase 2, and phase 3.

Type

  • Integrated services
  • Standalone services

On the basis of type, the cardiac safety services market is segmented into integrated services and standalone services.

End User

  • Pharmaceuticals & Biopharmaceuticals Companies
  • Contract Research Organizations
  • Academic and Research Institute

On the basis of end user, the cardiac safety services market is segmented pharmaceuticals & biopharmaceuticals companies, contract research organizations, and academic and research institute.

Cardiac Safety Services Regional Analysis/Insights

The cardiac safety services is analysed and market size insights and trends are provided by type, services, phase and end user as referenced above.

The countries covered in the cardiac safety services report are Germany, France, U.K., Italy, Spain, Turkey, Russia, Netherlands, Switzerland, Belgium and Rest of Europe.

Germany is expected to dominate due to increase in new drug development and healthcare expenditure.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Cardiac Safety Services Analysis

Europe cardiac safety services market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on cardiac safety services market.

Some major players in the market are Koninklijke Philips N.V., Laboratory Corporation of America Holdings, IQVIA, Medpace, Ncardia, Certara, Eurofins Scientific, SGS SA, Banook, and Celerion among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analysed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Europe Vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 PROPORTION OF WOMEN IN CLINICAL STUDIES, ACCORDING TO DEVELOPMENT PHASE

TABLE 2 PROBABILITY OF SUCCESS BY CLINICAL TRIAL PHASE TO THERAPEUTIC AREA

TABLE 3 MORTALITY RATES FROM CLINICAL TRIALS AND EUROPEAN SAFETY AND EXPOSURE SURVEY (ESES), DEATHS PER 100 (PYE)

TABLE 4 ADHERENCE RATE TO COMMON CARDIOVASCULAR MEDICATION

TABLE 5 PROPORTION OF WOMEN IN CLINICAL STUDIES, ACCORDING TO DEVELOPMENT PHASE

TABLE 6 INITIATIVES TO INCREASE ENROLLMENT IN CLINICAL TRIALS AMONG UNDERREPRESENTED POPULATIONS

TABLE 7 ESTIMATED COST OF CARDIAC SAFETY EVALUATION DEVICES

TABLE 8 EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 9 EUROPE ECG/HOLTER MEASUREMENTS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 EUROPE BLOOD PRESSURE MEASUREMENTS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 EUROPE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 EUROPE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 13 EUROPE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 14 EUROPE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 15 EUROPE CARDIOVASCULAR IMAGING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 EUROPE REAL TIME TELEMETRY MONITORING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 EUROPE CENTRAL OVER-READ OF ECGS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 EUROPE NON-INVASIVE CARDIAC IMAGING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 EUROPE PHYSIOLOGIC STRESS TESTING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 EUROPE THOROUGH QT STUDIES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 EUROPE TQT AND EXPOSURE RESPONSE MODELLING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 EUROPE PLATELET AGGREGATION IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 EUROPE OTHERS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 EUROPE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 25 EUROPE PHASE I IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 EUROPE PHASE II IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 EUROPE PHASE III IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 EUROPE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 29 EUROPE INTEGRATED SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 EUROPE STANDALONE SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 EUROPE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 32 EUROPE PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 EUROPE ACADEMIC AND RESEARCH INSTITUTE IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 EUROPE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 36 EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 37 EUROPE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 38 EUROPE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 39 EUROPE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 40 EUROPE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 41 EUROPE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 42 EUROPE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 43 GERMANY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 44 GERMANY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 45 GERMANY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 46 GERMANY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 47 GERMANY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 48 GERMANY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 GERMANY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 50 FRANCE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 51 FRANCE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 52 FRANCE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 53 FRANCE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 54 FRANCE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 55 FRANCE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 56 FRANCE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 57 U.K. CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 58 U.K. IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 59 U.K. HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 60 U.K. COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 61 U.K. CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 62 U.K. CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 63 U.K. CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 64 ITALY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 65 ITALY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 66 ITALY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 67 ITALY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 68 ITALY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 69 ITALY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 70 ITALY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 71 SPAIN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 72 SPAIN IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 73 SPAIN HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 74 SPAIN COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 75 SPAIN CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 76 SPAIN CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 77 SPAIN CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 78 TURKEY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 79 TURKEY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 80 TURKEY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 81 TURKEY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 82 TURKEY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 83 TURKEY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 84 TURKEY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 85 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 86 RUSSIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 87 RUSSIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 88 RUSSIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 89 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 90 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 91 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 92 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 93 NETHERLANDS IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 94 NETHERLANDS HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 95 NETHERLANDS COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 96 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 97 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 98 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 99 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 100 SWITZERLAND IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 101 SWITZERLAND HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 102 SWITZERLAND COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 103 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 104 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 105 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 106 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 107 BELGIUM IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 108 BELGIUM HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 109 BELGIUM COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

TABLE 110 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)

TABLE 111 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 112 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 113 REST OF EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The Europe Cardiac Safety Services Market will grow at a CAGR of 14.8% during the forecast by 2029.
The significant factors flourishing the growth of the Europe Cardiac Safety Services Market are Increase in healthcare expenditure and funding, and Increase in the number of clinical trials.
The major players operating in the Europe Cardiac Safety Services Market are Koninklijke Philips N.V., Laboratory Corporation of America Holdings, IQVIA, Medpace, Ncardia, Certara, Eurofins Scientific, SGS SA, Banook, and Celerion among others.
The major countries covered in the Europe Cardiac Safety Services Market are Germany, France, U.K., Italy, Spain, Turkey, Russia, Netherlands, Switzerland, Belgium and Rest of Europe.